Preclinical, in vitro, and in vivo studies suggest that breast and gastric cancer cell lines with FGFR2 amplifications may be sensitive to FGFR inhibitors (Jain and Turner 2012; Xie et al. 2013); clinical trials are ongoing. Here, FGFR2 is linked to gastric cancer.